· Published by Health Canada · Official notice
From the Marketed Health Products Directorate, Therapeutic Products Directorate, and the Health Products and Food Branch Inspectorate
February 17, 2003
To: Hospital Chief of Medical Staff
Please forward to the relevant Departments of Surgery; Otolaryngology; Pediatrics; Geriatrics; Internal Medicine; Intensive Care Units; Infection Control; Family Medicine; Emergency and involved professional staff and post this NOTICE in your institution.
On July 29, 2002, Health Canada issued a notice to hospitals entitled Cochlear Implant Recipients May be at Greater Risk for Meningitis. This notice provides an update on this issue, including updated information about the reported cases of bacterial meningitis and the cochlear implants themselves, factors that predispose cochlear implant recipients to bacterial meningitis, and immunization and prevention strategies. The original document may be found at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2002/implant_cochle_nth-ah-eng.php
Health Canada has become aware of new information about the possible increase of bacterial meningitis in cochlear implant recipients. In Canada, five cases of bacterial meningitis have been reported in patients with cochlear implants; three cases were in children and two in adults. One paediatric case was fatal. The time interval from implant to onset of meningitis ranged from 4.5 months to 4.25 years. Causative organisms identified include Streptococcus pneumoniae (3 cases), Haemophilus influenzae type f (1 case) and beta-haemolytic streptococcus group B (1 case).
The theoretical risk of developing bacterial meningitis in cochlear implant recipients has been known for some time but current epidemiologic studies may provide an assessment of the magnitude of this risk. To date, more than 90 cases have been reported worldwide in a population base of approximately 60,000 implantations. The US Food and Drug Administration advisory on this subject may be found at: www.fda.gov
In Canada, about 2000 people have received implants from two manufacturers: Cochlear Corporation (since 1987) and Advanced Bionics Corporation (since 1994). A third manufacturer, Med-EL has recently received a device licence for the Combi-40+ device.
What are Cochlear Implants?
Cochlear implants are medical devices that contain an electrode which is positioned in the cochlea (inner ear) to activate auditory nerve fibres allowing for transmission of sound signals to the brain.
What is bacterial meningitis?
Bacterial meningitis is an infection of the lining of the surface of the brain which is caused by certain bacteria. The yearly incidence of bacterial meningitis is approximately 3 to 5 cases per 100,000 population. (ref. Harrison's Principles of Internal Medicine, 14th Edition, 1998, p. 2419)
Early symptoms of meningitis include fever, irritability, lethargy and loss of appetite in infants and young children. Older children and adults may suffer from headache, stiff neck, photophobia, nausea and vomiting, and confusion or alteration in consciousness. Physicians should consider a diagnosis of meningitis in any patient, but especially in cochlear implant patients, when such symptoms exist. Children under 2 years of age have the highest risk of developing meningitis. The same bacteria cause meningitis in cochlear implant recipients as in other patients.
Predisposing Factors
The mechanism of infection for bacterial meningitis in cochlear implant recipients has not been established. The electrode of the cochlear implant is positioned in the inner ear, which is in close proximity to the brain. Some deaf people may have congenital abnormalities of the cochlea which predispose them to meningitis even prior to implantation. Individuals who became deaf as a result of meningitis may be at increased risk of subsequent episodes of meningitis. Surgical implantation of the device in a patient who has a middle ear infection may increase the risk of a post-operative infection of the inner ear, and subsequent meningitis. The cochlear implant, because it is a foreign body, may act as a source for infection when patients have bacterial illnesses. This minimal increase in risk is seen with all medical device implants.
One hypothesis for the increased risk of meningitis is that the design of the electrode with a positioner, as found in the Clarion™ HiFocus I and Hi Focus II may be a predisposing factor. Advanced Bionics Corporation now markets the Clarion™ HiFocus electrode without the positioner.
Prophylaxis:
Surgeons are encouraged to consider prophylactic antibiotic treatment prior to implantation, as appropriate, and physicians should diagnose and treat otitis media promptly in patients with cochlear implants.
Vaccination
Cochlear implant candidates, as well as those individuals who have already received the implant, may benefit from immunizations against organisms that are known to cause bacterial meningitis. All persons with implants and candidates for cochlear implants should be up-to-date with their immunizations. The National Advisory Committee on Immunization has made specific immunization recommendations for recipients of cochlear implants. These recommendations are available at: phac-aspc.gc.ca
What is Health Canada doing to address this situation?
Reporting Cases of Meningitis in Cochlear Implant Recipients
Health care professionals are reminded that most cases of bacterial meningitis are notifiable and should be promptly reported to your local Medical Officer of Health. Also, please report cases of meningitis in cochlear implant patients directly to the device manufacturer and to the Health Products and Food Branch Inspectorate of Health Canada at: 1-800-267-9675.
For additional information about the Health Products and Food Branch Inspectorate, please consult our website: Inspectorate website: